71924-12-4
71924-12-4
Chemical Structure
D-Glucosyl-β-N-palmitoylsphingosine-d3
Synonym(s): N-ω-CD3-Hexadecaoyl-glucopsychosie; GluCe(d18:1/16:0-d3); Glucosylceamide-d3 (d18:1/16:0-d3)
- CAS No.: 71924-12-4
- Formula:C40H74D3NO8
- Molecular Weight:703.06
InChIKey: VJLLLMIZEJJZTE-LKPYDFSUSA-N
SMILES: CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC(CCCCCCCCCCCCCCC([2H])([2H])[2H])=O)CO[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO
Biological Activity: D-Glucosyl-β-N-palmitoylsphingosine-d3 (N-ω-CD3-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine (HY-N10634). D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity[1][1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
D-Glucosyl-β-N-palmitoylsphingosine-d3 | 98% | D-Glucosyl-β-N-palmitoylsphingosine-d3 (N-ω-CD3-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine (HY-N10634). D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Glucosyl-β-1,1′-N-palmitoylsphingosine | 99.30% | D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl (β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand with immunostimulatory activity. D-Glucosyl-β-1,1′-N-palmitoylsphingosine binds to and activates macrophage-inducible C-type lectin (Mincle). D-Glucosyl-β-1,1′-N-palmitoylsphingosine is applicable to the research of immune system diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Pentadecanoyl-psychosine | 98.0% | N-Pentadecanoyl-psychosine is a glycolipid that can be used in membrane adhesion studies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C16 Galactosylceramide | 98.00% | C16 Galactosylceramide is a sphingolipid compound. C16 Galactosylceramide participates in the physiological processes of lipid metabolism and immune regulation in cells. C16 Galactosylceramide can be used in the study of diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GlcCer (d18:1/18:0) | 99.93% | GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipids that activates the Wnt/β-catenin pathway by targeting LRP6. GlcCer (d18:1/18:0) drives EMT, migration, invasion and GBA1-mediated liver cancer metastasis. GlcCer (d18:1/18:0) accumulates to impair lysosomal function and induce toxic α-synuclein aggregation. GlcCer (d18:1/18:0) supports growth, sporulation, germination and virulence in Penicillium digitatum. GlcCer (d18:1/18:0) is reduced in demyelinated mouse corpus callosum. GlcCer (d18:1/18:0) can be used for the research of liver cancer, synucleinopathies, fungal, Parkinson’s disease and Gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C17 Glucosyl(β) ceramide (d18:1/17:0) | C17 Glucosyl(β) ceramide (d18:1/17:0) is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C20 Galactosyl(ß) ceramide (d18:1/20:0) | 99% | C20 Galactosyl(?) ceramide (d18:1/20:0) is a β-Glucosyl ceramide. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C14 Galactosyl(ß) ceramide (d18:1/14:0) | C14 Galactosyl(β) ceramide (d18:1/14:0) is a β-Glucosyl ceramide. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C20 Glucosyl(β) ceramide (d18:1/20:0) | 99% | C20 Glucosyl(β) ceramide (d18:1/20:0) is a β-glucosyl ceramide. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C14 Glucosyl(ß) ceramide (d18:1/14:0) | C14 Glucosyl(β) ceramide (d18:1/14:0) is a β-Glucosyl ceramide. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
β-Galactosyl-C18-ceramide | β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
α-Galactosyl-C16-ceramide (d18:1/16:0) | α-Galactosyl-C16-ceramide (d18:1/16:0) is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Nagata M, et, al. Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity. Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3285-E3294. [Content Brief]
